GDMH join forces with Biotechnology Company Ascelia Pharma, which envisions the co-creation and co-development activities on the SPARKLE study held at Fondazione Policlinico Universitario A. Gemelli IRCCS.
Ascelia Pharma, a biotech focused on improving the life of people living with rare cancer conditions is conducting the pivotal Phase 3 clinical study
SPARKLE with the candidate drug Orviglance, a manganese-based MRI contrast agent for patients with liver lesions and severe renal impairment.